Latest Breaking News On - Ignacio melero - Page 3 : comparemela.com

CatalYm GmbH: CatalYm Commences Phase 2 Development of GDF-15-Targeting Antibody CTL-002 Following Successful Phase 1 Completion

CatalYm receives International Nonproprietary Name (INN) visugromab for CTL-002 as approved by the World Health Organization CatalYm today announced treatment of the first patients in a series of

CatalYm Commences Phase 2 Development of GDF-15-Targeting Antibody CTL-002 Following Successful Phase 1 Completion

Press release content from Business Wire. The AP news staff was not involved in its creation.

BioLineRx Announces Formation of Immuno-Oncology Scientific Advisory Board (SAB)

BioLineRx Announces Formation of Immuno-Oncology Scientific Advisory Board (SAB) - read this article along with other careers information, tips and advice on BioSpace

Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal, "Nature Communication"

Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal, "Nature Communication"